Cargando…

The Oxysterol 24(S),25-Epoxycholesterol Attenuates Human Smooth Muscle–Derived Foam Cell Formation Via Reduced Low-Density Lipoprotein Uptake and Enhanced Cholesterol Efflux

BACKGROUND: Foam cell formation by intimal smooth muscle cells (SMCs) inhibits the elaboration of extracellular matrix, which is detrimental to plaque stabilization. In the present study, we examined the lipoproteins and receptors involved in human SMC foam cell formation and investigated the abilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyea, Michael M., Reaume, Samantha, Sawyez, Cynthia G., Edwards, Jane Y., O'Neil, Caroline, Hegele, Robert A, Pickering, J Geoffrey, Huff, Murray W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487330/
https://www.ncbi.nlm.nih.gov/pubmed/23130136
http://dx.doi.org/10.1161/JAHA.112.000810
_version_ 1782248467902496768
author Beyea, Michael M.
Reaume, Samantha
Sawyez, Cynthia G.
Edwards, Jane Y.
O'Neil, Caroline
Hegele, Robert A
Pickering, J Geoffrey
Huff, Murray W
author_facet Beyea, Michael M.
Reaume, Samantha
Sawyez, Cynthia G.
Edwards, Jane Y.
O'Neil, Caroline
Hegele, Robert A
Pickering, J Geoffrey
Huff, Murray W
author_sort Beyea, Michael M.
collection PubMed
description BACKGROUND: Foam cell formation by intimal smooth muscle cells (SMCs) inhibits the elaboration of extracellular matrix, which is detrimental to plaque stabilization. In the present study, we examined the lipoproteins and receptors involved in human SMC foam cell formation and investigated the ability of 24(S),25-epoxycholesterol [24(S),25-EC], an oxysterol agonist of the liver X receptor, to attenuate SMC foam cell formation. METHODS AND RESULTS: Incubation of human internal thoracic SMCs with atherogenic lipoproteins demonstrated that low-density lipoprotein (LDL), but not oxidized or acetylated LDL, was the primary lipoprotein taken up, resulting in marked cholesteryl ester deposition (6-fold vs 1.8-fold; P<0.05; n=4). Exposure of SMCs to exogenous or endogenously synthesized 24(S),25-EC attenuated LDL uptake (−90% and −47% respectively; P<0.05; n=3) through decreased sterol regulatory element–binding protein-2 expression (−30% and −17%, respectively; P<0.001; n=3), decreased LDL receptor expression (−75% and −40%, respectively; P<0.05; n=3) and increased liver X receptor–mediated myosin regulatory light chain interacting protein expression (7- and 3-fold, respectively; P<0.05; n=4). Furthermore, exogenous 24(S),25-EC increased adenosine triphosphate–binding cassettes A1– and G1–mediated cholesterol efflux to apolipoprotein AI (1.9-fold; P<0.001; n=5) and high-density lipoprotein(3) (1.3-fold; P<0.05; n=5). 24(S),25-EC, unlike a nonsteroidal liver X receptor agonist, T0901317, did not stimulate sterol regulatory element–binding protein-1c–mediated fatty acid synthesis or triglyceride accumulation. 24(S),25-EC preserved the assembly of fibronectin and type I collagen by SMCs. CONCLUSIONS: The oxysterol 24(S),25-EC prevented foam cell formation in human SMCs by attenuation of LDL receptor–mediated LDL uptake and stimulation of cholesterol efflux, restoring the elaboration of extracellular matrix. In contrast to T0901317, 24(S),25-EC prevented the development of a triglyceride-rich foam cell phenotype. (J Am Heart Assoc. 2012;1:e000810 doi: 10.1161/JAHA.112.000810.)
format Online
Article
Text
id pubmed-3487330
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-34873302012-11-03 The Oxysterol 24(S),25-Epoxycholesterol Attenuates Human Smooth Muscle–Derived Foam Cell Formation Via Reduced Low-Density Lipoprotein Uptake and Enhanced Cholesterol Efflux Beyea, Michael M. Reaume, Samantha Sawyez, Cynthia G. Edwards, Jane Y. O'Neil, Caroline Hegele, Robert A Pickering, J Geoffrey Huff, Murray W J Am Heart Assoc Original Research BACKGROUND: Foam cell formation by intimal smooth muscle cells (SMCs) inhibits the elaboration of extracellular matrix, which is detrimental to plaque stabilization. In the present study, we examined the lipoproteins and receptors involved in human SMC foam cell formation and investigated the ability of 24(S),25-epoxycholesterol [24(S),25-EC], an oxysterol agonist of the liver X receptor, to attenuate SMC foam cell formation. METHODS AND RESULTS: Incubation of human internal thoracic SMCs with atherogenic lipoproteins demonstrated that low-density lipoprotein (LDL), but not oxidized or acetylated LDL, was the primary lipoprotein taken up, resulting in marked cholesteryl ester deposition (6-fold vs 1.8-fold; P<0.05; n=4). Exposure of SMCs to exogenous or endogenously synthesized 24(S),25-EC attenuated LDL uptake (−90% and −47% respectively; P<0.05; n=3) through decreased sterol regulatory element–binding protein-2 expression (−30% and −17%, respectively; P<0.001; n=3), decreased LDL receptor expression (−75% and −40%, respectively; P<0.05; n=3) and increased liver X receptor–mediated myosin regulatory light chain interacting protein expression (7- and 3-fold, respectively; P<0.05; n=4). Furthermore, exogenous 24(S),25-EC increased adenosine triphosphate–binding cassettes A1– and G1–mediated cholesterol efflux to apolipoprotein AI (1.9-fold; P<0.001; n=5) and high-density lipoprotein(3) (1.3-fold; P<0.05; n=5). 24(S),25-EC, unlike a nonsteroidal liver X receptor agonist, T0901317, did not stimulate sterol regulatory element–binding protein-1c–mediated fatty acid synthesis or triglyceride accumulation. 24(S),25-EC preserved the assembly of fibronectin and type I collagen by SMCs. CONCLUSIONS: The oxysterol 24(S),25-EC prevented foam cell formation in human SMCs by attenuation of LDL receptor–mediated LDL uptake and stimulation of cholesterol efflux, restoring the elaboration of extracellular matrix. In contrast to T0901317, 24(S),25-EC prevented the development of a triglyceride-rich foam cell phenotype. (J Am Heart Assoc. 2012;1:e000810 doi: 10.1161/JAHA.112.000810.) Blackwell Publishing Ltd 2012-06-22 /pmc/articles/PMC3487330/ /pubmed/23130136 http://dx.doi.org/10.1161/JAHA.112.000810 Text en © 2012 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley-Blackwell. http://creativecommons.org/licenses/by/2.5/ This is an Open Access article under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Beyea, Michael M.
Reaume, Samantha
Sawyez, Cynthia G.
Edwards, Jane Y.
O'Neil, Caroline
Hegele, Robert A
Pickering, J Geoffrey
Huff, Murray W
The Oxysterol 24(S),25-Epoxycholesterol Attenuates Human Smooth Muscle–Derived Foam Cell Formation Via Reduced Low-Density Lipoprotein Uptake and Enhanced Cholesterol Efflux
title The Oxysterol 24(S),25-Epoxycholesterol Attenuates Human Smooth Muscle–Derived Foam Cell Formation Via Reduced Low-Density Lipoprotein Uptake and Enhanced Cholesterol Efflux
title_full The Oxysterol 24(S),25-Epoxycholesterol Attenuates Human Smooth Muscle–Derived Foam Cell Formation Via Reduced Low-Density Lipoprotein Uptake and Enhanced Cholesterol Efflux
title_fullStr The Oxysterol 24(S),25-Epoxycholesterol Attenuates Human Smooth Muscle–Derived Foam Cell Formation Via Reduced Low-Density Lipoprotein Uptake and Enhanced Cholesterol Efflux
title_full_unstemmed The Oxysterol 24(S),25-Epoxycholesterol Attenuates Human Smooth Muscle–Derived Foam Cell Formation Via Reduced Low-Density Lipoprotein Uptake and Enhanced Cholesterol Efflux
title_short The Oxysterol 24(S),25-Epoxycholesterol Attenuates Human Smooth Muscle–Derived Foam Cell Formation Via Reduced Low-Density Lipoprotein Uptake and Enhanced Cholesterol Efflux
title_sort oxysterol 24(s),25-epoxycholesterol attenuates human smooth muscle–derived foam cell formation via reduced low-density lipoprotein uptake and enhanced cholesterol efflux
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487330/
https://www.ncbi.nlm.nih.gov/pubmed/23130136
http://dx.doi.org/10.1161/JAHA.112.000810
work_keys_str_mv AT beyeamichaelm theoxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT reaumesamantha theoxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT sawyezcynthiag theoxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT edwardsjaney theoxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT oneilcaroline theoxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT hegeleroberta theoxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT pickeringjgeoffrey theoxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT huffmurrayw theoxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT beyeamichaelm oxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT reaumesamantha oxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT sawyezcynthiag oxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT edwardsjaney oxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT oneilcaroline oxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT hegeleroberta oxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT pickeringjgeoffrey oxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux
AT huffmurrayw oxysterol24s25epoxycholesterolattenuateshumansmoothmusclederivedfoamcellformationviareducedlowdensitylipoproteinuptakeandenhancedcholesterolefflux